Skin Cancer News and Research

Latest Skin Cancer News and Research

MiNDERA closes $1 million Seed financing round

MiNDERA Corp., a leader in non-invasive molecular diagnostics for dermatology and skin-related cancers, announced today the close of its $1 million Seed financing round. Scientific Health Development and other individual investors are among MiNDERA's new investors. This financing round will enable MINDERA to further validate its proprietary micro-needle technology and prepare for the launch of its first research products.

12 Oct 2015

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel new research by a North Shore-LIJ Health System cancer surgeon.

12 Oct 2015

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

9 Oct 2015

Antioxidants can increase rate of melanoma metastasis in mice

Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice. The results reinforce previous findings that antioxidants hasten the progression of lung cancer. According to Professor Martin Bergö, people with cancer or an elevated risk of developing the disease should avoid nutritional supplements that contain antioxidants.

9 Oct 2015

Online advertising potentially effective in delivering targeted cancer prevention education

Online advertising based on Google search terms is a potentially effective way to deliver targeted cancer prevention education, according to a study led by Eleni Linos, MD, DrPH, an assistant professor of dermatology at UC San Francisco.

8 Oct 2015

Skin cancer rates higher among gay and bisexual men, UCSF-led study finds

Gay and bisexual men were up to six times more likely than heterosexual men to take part in indoor tanning, and twice as likely to report a history of skin cancer, including nonmelanoma and melanoma, according to a study led by UC San Francisco researchers.

8 Oct 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

28 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

SunSense UK’s nationwide tour highlights the dangers of intentional tanning

Sunscreen brand, SunSense, has this week completed a nationwide tour of the UK with the aim of encouraging the public to think twice about tanning.

15 Sep 2015

Desmoplasmic melanoma may possess unprecedented burden of gene mutations, say UCSF scientists

A rare, deadly form of skin cancer known as desmoplasmic melanoma (DM) may possess the highest burden of gene mutations of any cancer, suggesting that immunotherapy may be a promising approach for treatment, according to an international team led by UC San Francisco scientists. One of these mutations, never before observed in any cancer, may shield nascent DM tumors from destruction by the immune system and allow further mutations to develop.

7 Sep 2015

Aspirin may help boost effectiveness of cancer treatment

Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday).

3 Sep 2015

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UC San Francisco researchers.

3 Sep 2015

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells' ability to avoid detection and destruction by the immune system.

27 Aug 2015

New research finds five different types of prostate cancer

New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates.

25 Aug 2015

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.

21 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

Oncolytic virotherapy lends benefits to melanoma patients

Recent study published online by Melanoma Research journal indicates that melanoma patients would significantly benefit from prolonging the survival with oncolytic viroherapy treatment. The study revealed that the early stage melanoma patients treated with oncolytic medicine Rigvir were 4 to 6 times more likely to survive than those who following the current guidelines for the treatment of melanoma were only observed.

19 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

Organ transplant recipients more likely to develop melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and three times more likely to die of the dangerous skin cancer, suggests new research led by a Johns Hopkins Bloomberg School of Public Health student.

14 Aug 2015

Skin Cancer News and Research

Latest Skin Cancer News and Research

MiNDERA closes $1 million Seed financing round

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

Antioxidants can increase rate of melanoma metastasis in mice

Online advertising potentially effective in delivering targeted cancer prevention education

Skin cancer rates higher among gay and bisexual men, UCSF-led study finds

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Combination of two targeted therapies increases survival in advanced melanoma

SunSense UK’s nationwide tour highlights the dangers of intentional tanning

Desmoplasmic melanoma may possess unprecedented burden of gene mutations, say UCSF scientists

Aspirin may help boost effectiveness of cancer treatment

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

New research finds five different types of prostate cancer

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Oncolytic virotherapy lends benefits to melanoma patients

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

Organ transplant recipients more likely to develop melanoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Skin Cancer News and Research

Latest Skin Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in